Find Clinical Trials
A Phase Ib/II first-in-human, multicentre, open-label, multiple ascending dose study of S230815 in paediatric participants with KCNT1-related Developmental and Epileptic Encephalopathy
Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions.
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fasting Conditions
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.
Bioequivalence of One Tablet of Gliclazide MR 90 mg (S005190) and One and a Half Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.
Bioequivalence study of Fixed Dose Combination Gliclazide 60 mg + Metformin 1000 mg extended release tablet under fasting conditions
Ivosidenib chez des participants atteints de chondrosarcome conventionnel localement avancé ou métastatique, non traité ou ayant reçu un traitement systémique préalable (CHONQUER)
Étude d'Escalade de Dose de l'Administration Orale du S 55746 chez des Patients atteints de Leucémie Lymphoïde Chronique et de Lymphome Non-Hodgkinien à Cellules B
Étude de Phase I du S64315 Administré par Voie Intraveineuse chez des Patients atteints de Leucémie Myéloïde Aiguë ou de Syndrome Myélodysplasique
Étude de phase I d’escalade de dose portant sur le S64315 administré par voie intraveineuse en association avec le vénétoclax administré par voie orale chez des patients atteints de leucémie myéloïde aiguë
Essai de phase I/II portant sur S64315 plus azacitidine dans la leucémie myéloïde aiguë
Étude d'Escalade de Dose du UCART19 chez des Patients Adultes atteints de Leucémie Aiguë Lymphoblastique à Cellules B en Rechute / Réfractaire (CALM)
Étude de Prolongation pour Fournir un Traitement Continu avec la Pegaspargase Lyophilisée (S95014) chez des Patients Pédiatriques atteints de Leucémie Lymphoblastique Aiguë (LLA)
Première étude chez l’homme de phase Ib/II, multicentrique, en ouvert, à doses multiples croissantes, portant sur le S230815 chez des participants pédiatriques atteints d’encéphalopathie épileptique et développementale liée à KCNT-1
Essai de phase 1/2 du S241656 dans les cancers avec mutations RAS/MAPK
Étude à doses multiples sur la bioéquivalence d'un comprimé de Gliclazide MR 120 mg (S005190) et de deux comprimés de Gliclazide MR 60 mg (Diaprel® MR) chez des participants sains dans des conditions alimentaires.
Combinaison d'Ivosidenib, Nivolumab et Ipilimumab chez des sujets précédemment traités atteints de cholangiocarcinome mutant IDH1 non résécable ou métastatique.
Bioéquivalence d'un comprimé de gliclazide MR 120 mg (S005190) et de deux comprimés de gliclazide MR 60 mg (Diamicron® MR) chez des participants en bonne santé dans des conditions alimentaires
Bioéquivalence d'un comprimé de gliclazide MR 90 mg (S005190) et d'un comprimé et demi de gliclazide MR 60 mg (Diamicron® MR) chez des participants en bonne santé dans des conditions alimentaires
Bioequivalence study of Fixed Dose Combination Gliclazide 60 mg + Metformin 1000 mg extendedrelease tablet under fasting conditions
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation
A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Non-drug Treatment Study in Parkinson's Disease Patients and Healthy Volunteers to Collect Biological Samples in Order to Assess ex Vivo the Activity of Candidate Therapies and Develop Novel Analytical Methods for Biomarkers (IRIS-CLE-LRRK2)
Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.
An Experimental Medicine Clinical Study to Compare Peripheral Immune System From Subjects Without Cancer Diagnosis and Patients With Solid Tumours. (IMMUNOPBMC)
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH)
Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function